Video

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Jennifer Woyach, MD, a hematologist-oncologist and an associate professor within the Department of Internal Medicine at the Ohio State University Comprehensive Cancer Center–James, discusses the safety profile of acalabrutinib (Calquence) compared with ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL). 

The safety profile of acalabrutinib in CLL looks very promising, says Woyach. The rates of some of the toxicities that are associated with BTK inhibitors, such as atrial fibrillation, are relatively infrequent with acalabrutinib; however, this is probably seen a bit more with acalabrutinib than ibrutinib in the general population, notes Woyach.

Hypertension appears to be observed less with acalabrutinib, although it took several clinical trials, patients, and time to identify hypertension as a toxicity for ibrutinib, admits Woyach.

Some of the milder toxicities such as arthralgias and bruising appear less, as well, according to Woyach. Significant bleeding is also very rare with both agents, but it does not look like it is seen more with acalabrutinib compared with ibrutinib, concludes Woyach.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine